{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:57:50Z","timestamp":1790503070719,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bpobgyn.2019.05.003","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T21:23:43Z","timestamp":1557523423000},"page":"111-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Contraception in autoimmune diseases"],"prefix":"10.1016","volume":"60","author":[{"given":"Giuseppe","family":"Benagiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Benagiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Milco","family":"D'Elios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Brosens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2019.05.003_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/32.3.227","article-title":"Contraceptive practice in women with systemic lupus erythematosus","volume":"32","author":"Julkunen","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/acr.20402","article-title":"Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?","volume":"63","author":"Yazdany","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib3","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/1756-185X.12996","article-title":"Pregnancy outcomes and contraceptive use in patients with systemic lupus Erythematosus, rheumatoid arthritis and women without a chronic illness: a comparative study","volume":"20","author":"Galappatthy","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib4","article-title":"Low prevalence of contraceptive use among Brazilian women of reproductive age with systemic lupus erythematosus","author":"Bastos Brito","year":"2018","journal-title":"J\u00a0Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/00243639.2017.1360065","article-title":"Hormonal contraception and the development of autoimmunity: a review of the literature","volume":"84","author":"William","year":"2017","journal-title":"Linacre Q"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Cook MC Updated assessment of the prevalence, spectrum and case definition of autoimmune disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1365.002","article-title":"Contraception today","volume":"1092","author":"Benagiano","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/13625187.2011.614363","article-title":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17\u03b2-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function","volume":"16","author":"\u00c5gren","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.contraception.2009.03.018","article-title":"Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven cycle, randomized comparative trial of estradiol valerate\/dienogest and ethinyl estradiol\/levonorgestrel","volume":"80","author":"Ahrendt","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/13625187.2017.1336532","article-title":"Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control","volume":"22","author":"Apter","year":"2017","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"Suppl 1","key":"10.1016\/j.bpobgyn.2019.05.003_bib11","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","article-title":"Classification and pharmacology of progestin","volume":"46","author":"Schindler","year":"2003","journal-title":"Maturitas"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","article-title":"All progestins are not created equal","volume":"68","author":"Stanczyk","year":"2003","journal-title":"Steroids"},{"issue":"11","key":"10.1016\/j.bpobgyn.2019.05.003_bib13","first-page":"3765","article-title":"Effet de la contraception hormonale sur la nephropatie associ\u00e9e au lupus [Effect of hormonal contraception on the course of lupus nephropathy]","volume":"18","author":"Jungers","year":"1982","journal-title":"Nouv Presse Med"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780250603","article-title":"Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus","volume":"25","author":"Jungers","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/03009749109096822","article-title":"Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE","volume":"20","author":"Julkunen","year":"1991","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780400504","article-title":"Oral contraceptives and systemic lupus erythematosus","volume":"40","author":"Petri","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib17","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib18","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1056\/NEJMoa050817","article-title":"A\u00a0Trial of contraceptive methods in women with systemic lupus erythematosus","volume":"353","author":"Sanchez-Guerrero","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"9751","key":"10.1016\/j.bpobgyn.2019.05.003_bib19","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10067-007-0721-z","article-title":"Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies","volume":"27","author":"Choojitarom","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib23","first-page":"569","article-title":"Reduction in incidence of rheumatoid arthritis associated with oral contraceptives","volume":"1","author":"Wingrave","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(82)90809-1","article-title":"Oral contraceptives and rheumatoid arthritis: further evidence for a preventive effect","volume":"2","author":"Vandenbroucke","year":"1982","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.bpobgyn.2019.05.003_bib25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/rheumatology\/XXVIII.suppl_1.34","article-title":"Oral contraceptives and rheumatoid arthritis; further evidence for a protective effect independent of duration of pill use","volume":"28","author":"Hazes","year":"1989","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib26","first-page":"207","article-title":"The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study","volume":"31","author":"Doran","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/ard.2007.084707","article-title":"Breast feeding, but not use of oral contraceptives, is associated with a reduced risk of rheumatoid arthritis","volume":"68","author":"Pikwer","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/03009741003742763","article-title":"Influence of female hormonal factors, in relation to autoantibodies and genetic markers, on the development of rheumatoid arthritis in northern Sweden: a case\u2013control study","volume":"39","author":"Berglin","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib29","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/rheumatology\/ket456","article-title":"Breastfeeding practice, oral contraceptive use and risk of rheumatoid arthritis among Chinese women: the Guangzhou Biobank Cohort Study","volume":"53","author":"Adab","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib30","doi-asserted-by":"crossref","first-page":"R133","DOI":"10.1186\/ar2022","article-title":"Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides","volume":"8","author":"Pedersen","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.bpobgyn.2019.05.003_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/rheumatology\/XXVIII.suppl_1.13","article-title":"Oral contraceptives and the risk of rheumatoid arthritis: a meta-analysis of a conflicting literature","volume":"28","author":"Romieu","year":"1989","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib32","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/0895-4356(90)90023-I","article-title":"The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis","volume":"43","author":"Spector","year":"1990","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.aje.a008846","article-title":"Controversy of oral contraceptives and risk of rheumatoid arthritis: metaanalysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity","volume":"144","author":"Pladevall-Vila","year":"1996","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib34","first-page":"915","article-title":"Meta-analysis of oral contraceptives and rheumatoid arthritis risk in women","volume":"10","author":"Qi","year":"2014","journal-title":"Therapeut Clin Risk Manag"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5694\/j.1326-5377.1966.tb73454.x","article-title":"Oral contraceptives and tests of thyroid function","volume":"2","author":"Winikoff","year":"1966","journal-title":"Med J Aust"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0015-0282(16)36975-8","article-title":"The effect of an oral contraceptive on tests of thyroid function","volume":"20","author":"Mishell","year":"1969","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib37","first-page":"215","article-title":"Revue des effets de la contraception hormonale sur la fonction thyro\u00efdienne [A review of the effects of hormonal contraception on thyroid function]","volume":"71","author":"L'Hermite","year":"1976","journal-title":"Rev Fr Gyn\u00e9col Obstet"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib38","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.thromres.2013.12.041","article-title":"Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives","volume":"133","author":"Raps","year":"2014","journal-title":"Thromb Res"},{"issue":"5879","key":"10.1016\/j.bpobgyn.2019.05.003_bib39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/bmj.3.5879.513","article-title":"Depression of cellular immunity in pregnancy due to a serum factor","volume":"3","author":"Hill","year":"1973","journal-title":"Br Med J"},{"issue":"7863","key":"10.1016\/j.bpobgyn.2019.05.003_bib40","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0140-6736(74)90348-1","article-title":"Phytohaemagglutinin-induced lymphocyte transformation and circulating autoantibodies in women taking oral contraceptives","volume":"1","author":"Barnes","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib41","first-page":"30","article-title":"Changes of serum anti-thyroid antibodies during and after pregnancy in autoimmune thyroid diseases","volume":"31","author":"Amino","year":"1978","journal-title":"Clin Exp Immunol"},{"issue":"6151","key":"10.1016\/j.bpobgyn.2019.05.003_bib42","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/bmj.2.6151.1531","article-title":"Incidence of thyroid disease associated with oral contraceptives","volume":"2","author":"Frank","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib43","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1365-2265.2003.01862.x","article-title":"Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease","volume":"59","author":"Strieder","year":"2003","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0010-7824(93)90088-O","article-title":"Oral contraceptives and reproductive factors in multiple sclerosis incidence","volume":"47","author":"Villard-Mackintosh","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib45","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1471-0528.1998.tb10008.x","article-title":"The influence of oral contraceptives on the risk of multiple sclerosis","volume":"105","author":"Thorogood","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib46","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/WNL.55.6.848","article-title":"Oral contraceptives and the incidence of multiple sclerosis","volume":"55","author":"Hernan","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib47","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/archneur.62.9.1362","article-title":"Recent use of oral contraceptives and the risk of multiple sclerosis","volume":"62","author":"Alonso","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib48","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1212\/WNL.0b013e31825830a9","article-title":"Rising incidence of multiple sclerosis in females associated with urbanization","volume":"78","author":"Kotzamani","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149094","article-title":"Oral contraceptives and multiple sclerosis\/clinically isolated syndrome susceptibility","volume":"11","author":"Hellwig","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology","volume":"9","author":"Koch-Henriksen","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib51","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/1352458517701314","article-title":"Contraception for women with multiple sclerosis: guidance for healthcare providers","volume":"23","author":"Houtchens","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib52","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/gut.37.5.668","article-title":"Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease","volume":"37","author":"Godet","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib53","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/j.1572-0241.2008.02064.x","article-title":"The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis","volume":"103","author":"Cornish","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib54","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/BF01303165","article-title":"Oral contraceptive use and cigarette smoking in Crohn's disease","volume":"38","author":"Katschinski","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib55","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1590-8658(01)80693-9","article-title":"Environmental risk factors and Crohn's disease: a population-based, case-control study in Spain","volume":"33","author":"Sicilia","year":"2001","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib56","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/gutjnl-2012-302362","article-title":"Oral contraceptives, reproductive factors and risk of inflammatory bowel disease","volume":"62","author":"Khalili","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib57","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ibd.21747","article-title":"Role of genetic and environmental factors in British twins with inflammatory bowel disease","volume":"18","author":"Ng","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib58","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/oxfordjournals.aje.a117246","article-title":"Increased risk of inflammatory bowel disease associated with oral contraceptive use","volume":"140","author":"Boyko","year":"1994","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib59","first-page":"208","article-title":"Appendectomy is an independent protective factor for ulcerative colitis: results of a multicentre case control study. The Italian Group for the Study of the Colon and Rectum (GISC)","volume":"29","author":"Parrello","year":"1997","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib60","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.fertnstert.2011.05.025","article-title":"Steroid hormone hypersensitivity: clinical presentation and management","volume":"95","author":"Itsekson","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000248242","article-title":"Einege Daten zur Pathologie der Urticaria menstruationalis [Some data on the pathology of urticaria menstruationis]","volume":"32","author":"Geber","year":"1921","journal-title":"Dermatol Z"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib62","first-page":"195","article-title":"Premenstrual syndrome and associated skin diseases related to hypersensitivity to female sex hormones","volume":"49","author":"Itsekson","year":"2004","journal-title":"J\u00a0Reprod Med"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib63","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archderm.1977.01640040034003","article-title":"Autoimmune progesterone dermatitis","volume":"113","author":"Hart","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib64","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-7961-2-10","article-title":"Autoimmune progesterone dermatitis in a patient with endometriosis: case report and review of the literature","volume":"2","author":"Baptist","year":"2004","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1081-1206(10)61838-8","article-title":"Autoimmune progesterone dermatitis and its manifestation as anaphylaxis: a case report and literature review","volume":"90","author":"Snyder","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib66","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1111\/ajd.12529","article-title":"Autoimmune progesterone dermatitis: case report of an unexpected treatment reaction","volume":"58","author":"Cam\u00f5es","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib67","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaad.2007.10.646","article-title":"Autoimmune progesterone dermatitis associated with infertility treatment","volume":"58","author":"Jenkins","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0190-9622(95)90179-5","article-title":"Estrogen dermatitis","volume":"32","author":"Shelley","year":"1995","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib69","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/archderm.141.6.792","article-title":"Estrogen dermatitis: treatment with progestin-only pill","volume":"141","author":"Randall","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/DER.0000000000000064","article-title":"Estrogen dermatitis presenting as gyrate erythema treated with leuprolide","volume":"25","author":"Perdue","year":"2014","journal-title":"Dermatitis"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/15569527.2016.1245197","article-title":"Autoimmune estrogen dermatitis in an infertile female","volume":"36","author":"Elcin","year":"2017","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib72","series-title":"Progestogens in obstetrics and gynecology","first-page":"183","article-title":"Progestogens and autoimmunity","author":"Tsur","year":"2015"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0010-7824(01)00187-1","article-title":"Post-marketing surveillance of Norplant\u00ae contraceptive implants: II. Non-reproductive health","volume":"63","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib74","series-title":"Centers for disease control and prevention: international classification of diseases, Ninth revision (ICD-9)","year":"1999"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib75","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/01443615.2011.649320","article-title":"A\u00a0population-based case-control. study of aetiological factors associated with vulval lichen sclerosus","volume":"32","author":"Higgins","year":"2012","journal-title":"J\u00a0Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib76","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/13625180903519885","article-title":"State-of-the-art of non-hormonal methods of contraception: III. Intrauterine devices","volume":"15","author":"Sivin","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib77","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0039-128X(00)00176-8","article-title":"The levonorgestrel intrauterine system in contraception","volume":"65","author":"Lahteenmaki","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib78","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/humupd\/dmn003","article-title":"Intrauterine devices and intrauterine systems","volume":"14","year":"2008","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib79","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/trf.12865","article-title":"Autoimmune hemolytic anemia and thrombocytopenia attributed to an intrauterine contraceptive device","volume":"55","author":"Khawandanah","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib80","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/0144361021000082665","article-title":"Hypersensitivity to Mirena - a rare complication","volume":"23","author":"Pereira","year":"2003","journal-title":"J\u00a0Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib81","first-page":"99","article-title":"Intrauterine contraceptive device failures in renal transplant patients","volume":"26","author":"Zerner","year":"1981","journal-title":"J\u00a0Reprod Med"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib82","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0010-7824(87)90063-1","article-title":"Intrauterine devices and pelvic inflammatory diseases: recent developments","volume":"36","author":"Grimes","year":"1987","journal-title":"Contraception"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2007.03.031","article-title":"A\u00a0randomized trial of the intrauterine contraceptive device vs. hormonal contraception in women who are infected with the human immunodeficiency virus","volume":"197","author":"Stringer","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib84","series-title":"Medical eligibility criteria for contraceptive use: a family-planning cornerstone","year":"2015"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0002-9343(76)90431-9","article-title":"The bimodal mortality pattern of systemic lupus erythematosus","volume":"60","author":"Urowitz","year":"1976","journal-title":"Am J Med"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib86","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/096120339700600510","article-title":"Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus \u2013 a meta-analysis","volume":"6","author":"Wahl","year":"1997","journal-title":"Lupus"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib87","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib88","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/AOG.0b013e3181ec622b","article-title":"Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial","volume":"116","author":"Kaunitz","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib89","first-page":"1","article-title":"U.S. Medical eligibility criteria for contraceptive use","volume":"65","year":"2016","journal-title":"MMWR (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.bpobgyn.2019.05.003_bib90","series-title":"UK medical eligibility criteria for contraceptive use \u2013 UKMEC 2016","year":"2017"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169341930046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169341930046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:11:00Z","timestamp":1761498660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169341930046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":90,"alternative-id":["S152169341930046X"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2019.05.003","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contraception in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2019.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}